Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. 

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or Email: pdb@bioportfolio.co.uk
Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023

T cell is a type of white blood cell, and plays an important role in cell-mediated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient's body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells. The global engineered T cells market was valued at $145.97 million in 2016, and is estimated to reach at $2,124.02 million by 2023, registering a CAGR of 46.5% from 2017 to 2023.

Increase in of incidence of various types of cancers and autoimmune diseases is projected to drive the growth of the engineered T cells market. In addition, advantages offered by engineered T cells therapies over traditional cancer treatments such as chemotherapy, high technological advancements, and increase access to medical insurance are expected to boost the market growth. However, high cost associated with T cells therapies and lack of awareness about T cells therapies hinder the growth of this market.

The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into chimeric antigen receptor (CAR) modified T cells, tumor infiltrating lymphocytes (TIL), and T cells receptor (TCR) modified T cells. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia, and other applications. Depending on end user, it is fragmented into hospitals, cancer research centers, and clinics. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global engineered T-cells market and the current trends and future estimations to elucidate the imminent investment pockets.

It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.

Extensive analysis of the market based on end user assists to understand the trends in the industry.

Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type
Chimeric Antigen Receptor (CAR)
Tumor Infiltrating Lymphocytes (TIL)
T-cell Receptor (TCR)

By Application

Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Leukemia
Others

By End User

Hospitals
Cancer Research Centers
Clinics

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA

KEY PLAYERS PROFILED IN THE REPORT

Autolus Limited
Bellicum Pharmaceuticals, Inc.
Cell Medica
Elli Lilly and Company
Gilead Sciences, Inc.
Juno Therapeutics
Novartis AG
Oxford Biomedica
Pfizer Inc.
Precision Bioscience

The other players in the value chain include (profiles not included in the report)

Redmile Group
Seeking Alpha
Unum Therapeutics Inc.
Table Of Contents for Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023 [Report Updated: 01-01-2018]

• CHAPTER 1 INTRODUCTION
  1.1. REPORT DESCRIPTION
  1.2. KEY BENEFITS FOR STAKEHOLDERS
  1.3. KEY MARKET SEGMENTS
  1.4. RESEARCH METHODOLOGY
  1.4.1. Secondary research
  1.4.2. Primary research
  1.4.3. Analyst tools and models

• CHAPTER 2 EXECUTIVE SUMMARY
  2.1. KEY FINDINGS OF THE STUDY
  2.2. CXO PERSPECTIVE

• CHAPTER 3 MARKET OVERVIEW
  3.1. MARKET DEFINITION AND SCOPE
  3.2. KEY FINDINGS
  3.2.1. Top investment pockets
  3.2.2. Top winning strategies
  3.2.3. TOP WINNING STRATEGIES, BY YEAR, 2015-2017
  3.2.4. TOP WINNING STRATEGIES, BY COMPANY, 2015-2017
  3.3. PORTERS FIVE FORCES ANALYSIS
  3.3.1. Bargaining power of buyers
  3.3.2. Bargaining power of suppliers
  3.3.3. Threat of substitutes
  3.3.4. Threat of new entrants
  3.3.5. Competitive rivalry
  3.4. TOP PLAYER POSITIONING, 2016

• CHAPTER 4 ENGINEERED T CELLS
  4.1. OVERVIEW
  4.2. T CELLS RECEPTOR (TCR) MODIFIED T CELLS
  4.3. CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS
  4.4. TUMOR INFILTRATING LYMPHOCYTES

• CHAPTER 5 ENGINEERED T CELLS MARKET, BY APPLICATION
  5.1. OVERVIEW
  5.2. LUNG CANCER
  5.3. BREAST CANCER
  5.4. COLORECTAL CANCER
  5.5. MELANOMA
  5.6. OTHERS APPLICATIONS

• CHAPTER 6 ENGINEERED T CELLS MARKET, BY END USER
  6.1. OVERVIEW
  6.2. HOSPITALS
  6.3. CANCER RESEARCH CENTERS
  6.4. CLINICS

• CHAPTER 7 ENGINEERED T CELLS MARKET, BY REGION
  7.1. OVERVIEW
  7.2. NORTH AMERICA
  7.3. EUROPE
  7.4. ASIA-PACIFIC
  7.5. LATAM
  7.6. SOUTH AFRICA
  7.7. MIDDLE EAST AND AFRICA

• CHAPTER 8 COMPANY PROFILES
  8.1. COMPANY OVERVIEW
  8.2. BUSINESS PERFORMANCE
  8.3. COMPANY SNAPSHOTS
  8.4. CLINICAL TRIALS
  8.5. BUSINESS PERFORMANCE

https://www.bioportfolio.co.uk/product/182151
pdt@bioportfolio.co.uk to order
Key strategic moves and developments

8.3. CELL MEDICA LIMITED
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Clinical trials
8.3.5. Key strategic moves and developments

8.4. ELI LILLY AND COMPANY
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Clinical trials
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. GILEAD SCIENCES, INC. (KITE PHARMA INC.)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Clinical trials
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. JUNO THERAPEUTICS, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Clinical trials
8.6.4. Business performance
8.6.5. Key strategic moves and developments

8.7. NOVARTIS AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Clinical trials
8.7.5. Business performance

8.8. OXFORD BIOMEDICA PLC
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Clinical trials
8.8.5. Business performance

8.9. PFIZER INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Clinical trials
8.9.5. Business performance

8.10. PRECISION BIOSCIENCES INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Key strategic moves and developments
List Of Tables in Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023 [Report Updated: 01-01-2018]

TABLE 1. PROBABILITY OF DEVELOPING INVASIVE CANCER DURING SELECTED AGE GROUPS (%)
TABLE 2. MEDIAN MONTHLY PRICE OF GENERIC AND BRANDED CANCER MEDICINES
TABLE 3. GLOBAL ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 4. ENGINEERED T CELLS MARKET FOR CAR MODIFIED T CELLS, BY REGION, 2014-2022 ($MILLION)
TABLE 5. ENGINEERED T CELLS MARKET FOR TCR MODIFIED T CELLS, BY REGION, 2014-2022 ($MILLION)
TABLE 6. ENGINEERED T CELLS MARKET FOR TUMOR INFILTRATING LYMPHOCYTES, BY REGION, 2014-2022 ($MILLION)
TABLE 7. GLOBAL ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 8. ENGINEERED T CELLS MARKET FOR LUNG CANCER, BY REGION, 2014-2022 ($MILLION)
TABLE 9. ENGINEERED T CELLS MARKET FOR BREAST CANCER, BY REGION, 2014-2022 ($MILLION)
TABLE 10. ENGINEERED T CELLS MARKET FOR COLORECTAL CANCER, BY REGION, 2014-2022 ($MILLION)
TABLE 11. ENGINEERED T CELLS MARKET FOR MELANOMA, BY REGION, 2014-2022 ($MILLION)
TABLE 12. ENGINEERED T CELLS MARKET FOR LEUKEMIA, BY REGION, 2014-2022 ($MILLION)
TABLE 13. ENGINEERED T CELLS MARKET FOR OTHER APPLICATIONS, BY REGION, 2014-2022 ($MILLION)
TABLE 14. GLOBAL ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 15. ENGINEERED T CELLS MARKET FOR HOSPITALS, BY REGION, 2014-2022 ($MILLION)
TABLE 16. ENGINEERED T CELLS MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 2014-2022 ($MILLION)
TABLE 17. ENGINEERED T CELLS MARKET FOR CLINICS, BY REGION, 2014-2022 ($MILLION)
TABLE 18. ENGINEERED T CELLS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA ENGINEERED T CELLS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20. NORTH AMERICA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 21. NORTH AMERICA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
<table>
<thead>
<tr>
<th>Table Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>North America Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>23</td>
<td>U.S. Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>24</td>
<td>U.S. Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>25</td>
<td>U.S. Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>26</td>
<td>Canada Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>27</td>
<td>Canada Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>28</td>
<td>Canada Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>29</td>
<td>Mexico Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>30</td>
<td>Mexico Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>31</td>
<td>Mexico Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>32</td>
<td>European Engineered T Cells Market, by Country, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>33</td>
<td>European Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>34</td>
<td>European Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>35</td>
<td>European Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>36</td>
<td>Germany Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>37</td>
<td>Germany Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>38</td>
<td>Germany Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>39</td>
<td>France Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>40</td>
<td>France Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>41</td>
<td>France Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>42</td>
<td>UK Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>43</td>
<td>UK Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>44</td>
<td>UK Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>45</td>
<td>Italy Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>46</td>
<td>Italy Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>47</td>
<td>Italy Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>48</td>
<td>Spain Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>49</td>
<td>Spain Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>50</td>
<td>Spain Engineered T Cells Market, by End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>51</td>
<td>Rest of Europe Engineered T Cells Market, by Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>52</td>
<td>Rest of Europe Engineered T Cells Market, by Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table Number</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Table 53</td>
<td>Rest of Europe Engineered T Cells Market, By End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 54</td>
<td>Asia-Pacific Engineered T Cells Market, By Country, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 55</td>
<td>Asia-Pacific Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 56</td>
<td>Asia-Pacific Engineered T Cells Market, By Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 57</td>
<td>Asia-Pacific Engineered T Cells Market, By End-User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 58</td>
<td>Japan Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 59</td>
<td>Japan Engineered T Cells Market, By Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 60</td>
<td>Japan Engineered T Cells Market, By End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 61</td>
<td>China Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 62</td>
<td>China Engineered T Cells Market, By Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 63</td>
<td>China Engineered T Cells Market, By End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 64</td>
<td>India Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 65</td>
<td>India Engineered T Cells Market, By Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 66</td>
<td>India Engineered T Cells Market, By End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 67</td>
<td>Australia Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 68</td>
<td>Australia Engineered T Cells Market, By Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 69</td>
<td>Australia Engineered T Cells Market, By End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 70</td>
<td>South Korea Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 71</td>
<td>South Korea Engineered T Cells Market, By Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 72</td>
<td>South Korea Engineered T Cells Market, By End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 73</td>
<td>Taiwan Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 74</td>
<td>Taiwan Engineered T Cells Market, By Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 75</td>
<td>Taiwan Engineered T Cells Market, By End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 76</td>
<td>Rest of Asia-Pacific Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 77</td>
<td>Rest of Asia-Pacific Engineered T Cells Market, By Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 78</td>
<td>Rest of Asia-Pacific Engineered T Cells Market, By End User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 79</td>
<td>LAMEA Engineered T Cells Market, By Country, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 80</td>
<td>LAMEA Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 81</td>
<td>LAMEA Engineered T Cells Market, By Application, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 82</td>
<td>LAMEA Engineered T Cells Market, By End-User, 2016-2023 ($Million)</td>
</tr>
<tr>
<td>Table 83</td>
<td>Brazil Engineered T Cells Market, By Type, 2016-2023 ($Million)</td>
</tr>
</tbody>
</table>
TABLE 84. BRAZIL ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 85. BRAZIL ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 86. TURKEY ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 87. TURKEY ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 88. TURKEY ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 89. SAUDI ARABIA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 90. SAUDI ARABIA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 91. SAUDI ARABIA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 92. SOUTH AFRICA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 93. SOUTH AFRICA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 94. SOUTH AFRICA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 95. REST OF LAMEA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 96. REST OF LAMEA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 97. REST OF LAMEA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 98. AUTOLUS LIMITED: COMPANY SNAPSHOT
TABLE 99. BELLICUM PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 100. BELLICUM PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 101. CELL MEDICA LIMITED: COMPANY SNAPSHOT
TABLE 102. CELL MEDICA LIMITED: OPERATING SEGMENTS
TABLE 103. CELL MEDICA LIMITED: PRODUCT PORTFOLIO
TABLE 104. LILLY: COMPANY SNAPSHOT
TABLE 105. LILLY: OPERATING SEGMENTS
TABLE 106. GILEAD SCIENCE INC.: COMPANY SNAPSHOT
TABLE 107. GILEAD SCIENCE INC.: OPERATING SEGMENTS
TABLE 108. GILEAD SCIENCE, INC.: PRODUCT PORTFOLIO
TABLE 109. JUNO THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 110. JUNO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 111. NOVARTIS: COMPANY SNAPSHOT
TABLE 112. NOVARTIS: OPERATING SEGMENTS
TABLE 113. NOVARTIS: PRODUCT PORTFOLIO
TABLE 114. KEY STRATEGIC MOVES AND DEVELOPMENTS
List Of Figures, Charts and Diagrams in Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023 [Report Updated: 01-01-2018]

FIGURE 1. MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP PLAYER POSITIONING: ENGINEERED T CELLS MARKET, 2016
FIGURE 4. PERCENTAGE OF GOVERNMENT EXPENDITURE ON HEALTHCARE, 2013-2014
FIGURE 5. PERCENTAGE DISTRIBUTION OF POPULATION AGED 65 YEARS AND ABOVE BY REGION: 2015, 2030 AND 2050
FIGURE 6. ESTIMATED NUMBER OF DEATHS DUE TO CANCER, U.S., 2015 AND 2017
FIGURE 7. REIMBURSEMENT STATUS OF CANCER MEDICINES APPROVED IN 2014 AND 2015
FIGURE 8. ENGINEERING PROCESS FOR CAR MODIFIED T CELLS
FIGURE 9. ENGINEERED T CELLS MARKET FOR CAR MODIFIED T CELLS, BY COUNTRY, 2016 (%)
FIGURE 10. ENGINEERED T CELLS MARKET FOR TCR MODIFIED T CELLS, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 11. ENGINEERED T CELLS MARKET FOR TUMOR INFILTRATING LYMPHOCYTES, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 12. ENGINEERED T CELLS MARKET FOR LUNG CANCER, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 13. ENGINEERED T CELLS MARKET FOR BREAST CANCER, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 14. ENGINEERED T CELLS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 15. ENGINEERED T CELLS MARKET FOR MELANOMA, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 16. ENGINEERED T CELLS MARKET FOR LEUKEMIA, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 17. ENGINEERED T CELLS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 18. ENGINEERED T CELLS MARKET FOR HOSPITALS, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 19. ENGINEERED T CELLS MARKET FOR CANCER RESEARCH CENTERS, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 20. ENGINEERED T CELLS MARKET FOR CLINICS, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 52. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 53. OXFORD BIOMEDICA: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. OXFORD BIOMEDICA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 55. OXFORD BIOMEDICA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 56. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 58. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
How to Buy...

Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023 [Report Updated: 01-0-2018]

**Option 1 - Online**
Go to our website and pay online with any major debit or credit card:
[https://www.bioportfolio.co.uk/product/182151](https://www.bioportfolio.co.uk/product/182151)

**Option 2 - Request a Proforma Invoice**
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

- **Your Name:**
- **Job Title:**
- **Your Email:**
- **Your Contact Phone:**
- **Company Name:**
- **Address:**
- **Post/Zip Code:**
- **Country:**
- **P.O. Number:**
- **Any Other Instructions:**

**Pricing Options:** (please tick one)
- $3840 | Single User Price
- $5910 | Enterprise License Price

**Payment Options:** (please tick one)
- **Online Credit Card** (we will email you the invoice with a payment link)
- **Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:**

**Option 3 - Phone Us on +44 (0)7887 945155**
We will be delighted to give you our personal attention.